Morgan Stanley Initiates Coverage on Genzyme (GENZ) with an Overweight
More News related to GENZ
- David Moenning’s Daily State of the Markets: 6/26
- Goldman Sachs Lowers Price Target On Genzyme (GENZ); Maintains Sell
- Genzyme Reports Progress Related to Allston Plant
- RBC Capital Initiates Coverage on Genzyme (GENZ) with an Outperform
- Baird Is a Buyer of BioMarin (BMRN) On Genzyme-Related Weakness
Morgan Stanley initiates coverage on Genzyme (Nasdaq: GENZ) with an Overweight rating. Price target $94.
Genzyme Corporation is a biotechnology company.
Related Categories
New CoverageStocks Mentioned
-0.67Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
